
BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
New funding transforms lives by expanding electricity access across Africa - 2
After harsh winter, Ukrainians find joy in releasing bats rescued from war - 3
Australia’s post-Bondi crackdown accused of targeting pro-Palestinian voices - 4
Inside Kathy Hilton’s Christmas pajama party: caviar bumps, champagne vending machines and a mansion full of Housewives - 5
What to know about cheese voluntarily recalled in 20 states
Qantas and Virgin Australia Ban Power Bank Usage on Flights Following Safety Incidents
Iran, Hezbollah fire rockets at Israel during Passover celebrations
Los Angeles County sees significant uptick in norovirus cases, officials say
Nigeria warns its citizens in South Africa to be cautious after march turns violent
Monetary Security: Building Serious areas of strength for an Establishment
NASA’s Artemis II launch leaves Americans in awe: ‘We’re going to the frickin’ moon!’
‘Wu-Tang Forever: The Final Chamber’ tour — How to get tickets, presale times, concert dates and more
Did we start the fire? A 400,000-year-old hearth sparks new questions about human evolution
Instructions to Warmly greet Certainty and Appeal













